公司概述
United Therapeutics Corporation is dedicated to the development and commercialization of therapeutic products designed to address unmet medical needs for patients suffering from chronic and life-threatening diseases within both the United States and international markets. The company operates within the Healthcare sector, specifically classified under the Drug Manufacturers - Specialty & Generic industry, a classification that highlights its focus on specialized pharmaceutical solutions rather than broad commodity drugs. As of the latest available data, the entity maintains a substantial market capitalization of $25.49B, generates annual revenue of $3.18B, and employs a workforce of 1400 individuals. These valuation and revenue figures indicate that United Therapeutics holds a significant position in the specialty pharmaceutical landscape, commanding a large market value that reflects the high demand for its specialized therapies and the substantial scale of its operational footprint.
财务健康
The company reports a trailing twelve-month revenue of $3.18B, with corresponding net income of $1.33B and EBITDA of $1.60B. The gap between the $3.18B in revenue and the $1.33B in net income reveals a cost structure where operating expenses and taxes consume approximately 58.2% of total sales, a typical characteristic for pharmaceutical firms with high research and development costs. United Therapeutics demonstrates robust financial flexibility with free cash flow of $582.01M, a metric that signifies the company generates ample cash from operations to fund its R&D initiatives, capital expenditures, or potential strategic acquisitions without relying heavily on external financing. The company's profitability is underpinned by exceptional margins, including a gross margin of 87.9%, an operating margin of 45.0%, and a profit margin of 41.9%, all of which indicate highly efficient production processes and strong pricing power in the specialty drug market. Regarding its balance sheet, United Therapeutics holds $2.92B in cash against a minimal debt load of $37.60M, resulting in a debt-to-equity ratio of 0.53, which characterizes the firm as highly conservative and financially resilient against liquidity shocks. Short-term liquidity is further evidenced by a current ratio of 6.61, a figure that suggests the company possesses more than six times the current assets necessary to cover its short-term liabilities, ensuring operational continuity. Furthermore, the return on equity stands at 19.7% while the return on assets is 12.4%, metrics that collectively reveal that management is effectively deploying shareholder capital and utilizing company assets to generate superior returns relative to industry averages.
估值评估
Valuation metrics for United Therapeutics show a trailing P/E ratio of 20.88 and a forward P/E of 17.09. The difference between these two ratios, with the forward multiple being significantly lower, implies that the market expects earnings growth to outpace the current earnings base, leading to a compression in the multiple over time. The price-to-book ratio is recorded at 3.58, indicating that the market prices the company at a substantial premium of roughly 258% over its tangible book value, reflecting the intangible value of its intellectual property and patent portfolios. Alternative valuation measures such as the price-to-sales ratio of 8.01 and an EV/EBITDA of 14.12 suggest that the company is valued based on its sales scale and earnings power, metrics that are often preferred for capital-intensive or high-growth biotech and pharma firms where traditional P/E multiples can be distorted by non-recurring R&D costs. In terms of price volatility, the stock has traded between a 52-week low of $266.98 and a 52-week high of $607.89. Without the specific current share price provided in the data to calculate an exact percentage deviation, the trading range establishes a band within which the asset has fluctuated over the past year, with a beta of 0.75 indicating that the stock's price movements are less volatile than the broader market, moving only 75% as much as the market index.
Growth & Income
United Therapeutics exhibits a revenue growth rate of 7.4% year-over-year alongside an earnings growth rate of 24.5% year-over-year. The disparity between these two figures, where earnings are growing at more than three times the rate of revenue, implies significant operating leverage and efficiency improvements that are translating into disproportionate profit growth. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning that all generated earnings are retained and reinvested directly into research, development, and commercial expansion rather than being distributed to shareholders. This reinvestment strategy supports long-term organic growth in the specialty drug sector, where maintaining a robust pipeline of approved and pipeline therapies is critical for sustaining future revenue streams. Overall, the growth and income profile of United Therapeutics is defined by high earnings expansion driven by operational efficiency and a capital allocation strategy focused on reinvestment rather than immediate shareholder yield.